Joe Rogan TRT: How a Regular Patient Would Get Access

What Joe Rogan Has Actually Said About TRT

Joe Rogan has not hidden his use of testosterone replacement therapy. On episode #1681 of The Joe Rogan Experience, he described his regimen explicitly, naming testosterone, HGH, and NAD+ as part of his routine. On episode #1474, he told guest Kelly Slater that he gets bloodwork done regularly and adjusts compounds based on results. These are his own words, not inference.

That transparency matters clinically. Rogan is not an outlier. The American Urological Association estimates that roughly 2.4 million men in the United States receive testosterone therapy, and that number has risen steadily since 2000.

What Rogan Specifically Mentioned

Across multiple episodes, Rogan has named:

• Testosterone (the hormone itself, administered by injection)
• HGH (human growth hormone) prescribed off-label by an anti-aging physician
• NAD+ infusions for cellular energy and cognitive function
• Peptides such as BPC-157, referenced in the context of injury recovery

The clinical access pathways for each of these differ. Testosterone requires a hypogonadism diagnosis. HGH requires documented adult growth hormone deficiency on stimulation testing per FDA labeling. NAD+ infusions are not FDA-approved as a drug product but are administered as compounded preparations. Peptides like BPC-157 are research compounds with no current FDA approval for human use, so they sit outside standard clinical prescribing.

This article focuses on testosterone, the compound with the clearest evidence base and the most accessible legitimate pathway for patients.

Who Actually Qualifies for TRT

Diagnosis is the gate. A clinician cannot legally or ethically prescribe testosterone to a eugonadal man simply because he wants higher levels. The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states that treatment should be offered to men with "classic androgen deficiency syndromes" confirmed by both symptoms and biochemistry. [1]

The Two-Draw Rule

The guideline requires two separate morning fasting draws (collected between 7 and 10 a.m.) showing total testosterone below 300 ng/dL, with symptoms present. [1] A single low result is not enough. Morning timing matters because testosterone peaks at approximately 8 a.m. And declines by 20 to 25% across the day, so an afternoon draw can falsely depress the result.

Symptoms That Support the Diagnosis

Biochemistry alone does not make the diagnosis. Clinicians look for:

• Reduced libido
• Erectile dysfunction
• Fatigue and decreased energy despite adequate sleep
• Loss of muscle mass or increased body fat
• Depressed mood not explained by primary psychiatric illness
• Decreased bone mineral density

The Endocrine Society guideline specifies that clinicians should "confirm the diagnosis before initiating treatment" and avoid treating men who are asymptomatic even if testosterone is borderline low. [1]

Secondary Causes to Rule Out

Before prescribing, a physician should rule out secondary causes of low testosterone: hyperprolactinemia, hemochromatosis, pituitary adenoma, and use of opioids or anabolic steroids. Opioid-induced androgen deficiency is clinically distinct from primary hypogonadism and requires a different management approach, as detailed in a 2018 review in the Journal of Clinical Endocrinology and Metabolism. [2]

The Full Lab Panel a Clinician Orders

Getting TRT is not just about total testosterone. A responsible prescriber orders a panel that protects the patient from harm and establishes legal documentation of medical necessity.

Pre-Treatment Labs

| Lab | Why It Matters | |---|---| | Total testosterone (AM) | Diagnostic threshold <300 ng/dL | | Free testosterone | Clarifies borderline total T cases | | LH and FSH | Distinguishes primary from secondary hypogonadism | | Estradiol (E2) | Baseline before aromatization increases | | CBC with hematocrit | TRT raises red cell mass; baseline needed | | PSA | Required before T in men over 40 per AUA guideline | | Metabolic panel | Liver function, renal function | | Lipid panel | T can modestly lower HDL | | Prolactin | Screens for prolactinoma as a cause |

A 2020 study in JAMA Internal Medicine found that among men newly prescribed testosterone in U.S. Ambulatory settings, only 74.7% had a testosterone level measured in the 12 months before starting therapy, and fewer than half had a confirmatory second draw. [3] That represents a documentation and safety gap, not a model to follow.

Ongoing Monitoring Labs

The Endocrine Society guideline recommends checking testosterone levels, hematocrit, and PSA at 3 and 6 months after initiation, then annually. [1] Hematocrit above 54% is grounds for dose reduction or phlebotomy, given the thrombosis risk documented in the TTrials program. [4]

Standard TRT Protocols: Doses and Delivery Methods

Once diagnosis is confirmed, the prescriber selects a delivery method. Each has real tradeoffs.

Intramuscular and Subcutaneous Injections

Testosterone cypionate and testosterone enanthate are the most commonly prescribed formulations in the United States. Standard dosing ranges from 100 to 200 mg administered intramuscularly or subcutaneously every 7 to 14 days. [1] Subcutaneous injection into the abdomen or thigh produces slower absorption and smoother hormone levels than deep intramuscular injection, and a 2017 study in the Journal of Urology confirmed comparable serum levels with fewer local side effects. [5]

Rogan has referenced injections specifically. This aligns with the most cost-effective and pharmacokinetically predictable delivery method.

Topical Gels and Creams

AndroGel 1.62% (testosterone gel) is FDA-approved and applied daily to the shoulders or upper arms. The main limitation is transfer risk to female partners and children. The FDA added a black-box warning for this reason in 2009. [6] Gels produce stable daily levels but require consistent morning application and skin-to-skin contact precautions for roughly two hours post-application.

Testosterone Pellets

Subcutaneous pellet implants (brand name Testopel) deliver testosterone over 3 to 6 months. Each pellet is implanted in the buttock or flank under local anesthesia. Dosing is typically 150 to 450 mg per implant session. The advantage is compliance; the patient does not have to remember daily applications or weekly injections. The disadvantage is inflexibility: if levels run too high, there is no way to reduce the dose until the pellets dissolve.

What About HCG?

Many TRT protocols add human chorionic gonadotropin (hCG) to preserve testicular size and fertility. HCG mimics luteinizing hormone and stimulates intratesticular testosterone production. The Endocrine Society guideline recommends considering hCG co-administration in men who wish to maintain fertility while on TRT. [1] The standard dose is 500 IU subcutaneously two to three times per week. Rogan has referenced concern about testicular atrophy in podcast conversations, which is the exact clinical indication for adding hCG.

NAD+ Therapy: The Evidence Base

Rogan has described NAD+ infusions as part of his recovery and cognitive-function routine. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to mitochondrial oxidative phosphorylation.

What the Research Shows

A 2023 randomized controlled trial published in Nature Aging (N=60) found that oral NMN supplementation, a NAD+ precursor, increased whole-blood NAD+ levels by 38% at 60 days compared to placebo (P<0.001). [7] Functional outcomes including grip strength and six-minute walk distance showed modest but statistically significant improvement in adults over 65.

IV NAD+ infusions deliver the compound directly into circulation, bypassing intestinal absorption. There are no large randomized controlled trials of IV NAD+ in otherwise healthy middle-aged adults as of early 2025. The evidence base supports preclinical and early human data, not yet a guideline-level recommendation.

Compounded IV NAD+ is administered at doses typically ranging from 250 mg to 1,000 mg per infusion session. Sessions are often run over 2 to 4 hours due to the flushing and chest tightness that can occur with rapid infusion rates.

The table below summarizes the access pathway for each compound Rogan has discussed, organized by regulatory and clinical requirements a regular patient would face.

| Compound | FDA Status | Requires Diagnosis | Typical Prescriber | Telehealth Eligible | |---|---|---|---|---| | Testosterone cypionate | Approved (Schedule III) | Yes: hypogonadism | MD, DO, NP, PA | Yes, with in-state DEA registration | | HGH (somatropin) | Approved (narrow indications) | Yes: adult GHD on stimulation test | Endocrinologist preferred | Limited | | NAD+ IV | Compounded (503A/503B) | No formal diagnosis required | MD, DO, NP, PA | Partial (requires infusion site) | | BPC-157 | No FDA approval | N/A | Research use only | Not eligible |

How to Actually Get TRT as a Regular Patient

The path from suspicion to prescription involves four concrete steps. None of them require a podcast or a celebrity physician.

Step 1: Get a Baseline Blood Draw

Order or ask your primary care physician for a morning fasting testosterone panel. Alternatively, direct-to-consumer lab services such as Labcorp and Quest Diagnostics allow patients to self-order a testosterone panel without a physician order in most states. The cost runs from $30 to $80 out of pocket.

The draw must be before 10 a.m. Repeat it on a separate day if the result is below 400 ng/dL, because borderline results fluctuate.

Step 2: Identify a Prescriber

Three types of prescribers handle the majority of TRT in the United States:

1. Primary care physicians (internists, family medicine) who are comfortable with hormone management.
2. Urologists, who manage hypogonadism per the AUA Male Hypogonadism Guideline (2018, amended 2022). [8]
3. Telehealth TRT platforms with DEA-registered prescribers in your state, which allow video consultation plus at-home bloodwork through a partnered lab.

The AUA guideline notes that urologists "should be familiar with the diagnosis and management of testosterone deficiency" and references the 2018 Endocrine Society document as the supporting evidence base. [8]

Step 3: Complete the Full Pre-Treatment Panel

Do not accept a prescription based on a single total testosterone value. Insist on the complete panel described in the lab section above. A prescriber who skips LH/FSH, PSA, and hematocrit before starting testosterone is not following guideline-concordant care.

Step 4: Start Low and Titrate

Standard practice is to start at the lower end of the therapeutic range (100 mg testosterone cypionate per week or 50 mg twice weekly for smoother levels) and recheck labs at 6 to 8 weeks. The therapeutic target for most guidelines is a mid-range normal testosterone level of 400 to 700 ng/dL, not supraphysiologic levels. [1]

Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital and lead author of the Endocrine Society guideline, has stated: "The goal of testosterone therapy is to restore testosterone concentrations to the normal range for healthy young men, not to achieve the highest possible levels." [1]

Risks Every Patient Should Know Before Starting

TRT is not risk-free. The TRAVERSE trial (N=5,198 men aged 45 to 80 with hypogonadism and cardiovascular risk factors) found no significant increase in major adverse cardiovascular events with testosterone undecanoate versus placebo over a median 33 months of follow-up. [9] This was a landmark result, because cardiovascular risk had been the central safety concern for two decades. The trial did find a statistically significant increase in non-fatal arrhythmias, pulmonary embolism, and acute kidney injury in the testosterone group, so the cardiovascular picture is not entirely clean. [9]

Other established risks include:

• Erythrocytosis: Hematocrit above 54% in roughly 3 to 18% of patients depending on dose and delivery method. [1]
• Infertility: Exogenous testosterone suppresses LH and FSH, shutting down spermatogenesis. This is reversible in most men after stopping, but recovery can take 12 to 24 months.
• Sleep apnea exacerbation: Documented in a meta-analysis of 51 trials published in the Journal of Clinical Sleep Medicine. [10]
• Acne and skin changes: Androgen-driven sebaceous gland activity increases in most patients.

The Telehealth Pathway: What to Expect

Since 2020, DEA-registered telehealth prescribers have been able to initiate testosterone therapy after a video consultation under the COVID-19 public health emergency flexibilities. As of early 2025, proposed DEA rules would require at least one in-person visit for Schedule III controlled substances. Patients should verify current rules in their state before assuming fully remote prescribing is available.

A typical telehealth TRT intake process runs as follows:

1. Patient completes symptom questionnaire online.
2. Platform orders bloodwork at a partnered lab (patient visits a local draw site).
3. Video consultation with a licensed prescriber to review results and history.
4. If criteria are met, prescription sent to a compounding or retail pharmacy.
5. Medication ships directly to the patient.

Monthly costs at telehealth platforms range from approximately $100 to $250 for testosterone cypionate with supplies, excluding labs. Branded gels (AndroGel, Testim) cost substantially more and may require insurance coverage.

A Practical Note on Celebrity Protocols vs. Patient Protocols

Rogan has mentioned doses and compounds that extend well beyond standard clinical TRT. His references to HGH, peptides, and high-dose testosterone cycles reflect access to a concierge anti-aging physician operating in a medically legal but evidence-light space.

The TTrials, a coordinated set of seven double-blind RCTs funded by the National Institute on Aging (N=790 men aged 65 and older), evaluated testosterone at doses that produced mid-normal serum levels, not supraphysiologic levels. [4] Benefits included improved sexual function, bone mineral density, and anemia correction. Physical function improvements were modest and not statistically significant in the main functional mobility endpoint.

A patient replicating "Joe Rogan's protocol" in its entirety would need a physician willing to prescribe HGH off-label (which requires documented adult GHD per FDA labeling) [11] and peptides that lack FDA approval. Testosterone itself, by contrast, is fully accessible through the standard pathway described above.